SEARCH

SEARCH BY CITATION

References

  • Alessandrino, E.P., Amadori, S., Barosi, G., Cazzola, M., Grossi, A., Liberato, L.N., Locatelli, F., Marchetti, M., Morra, E., Rebulla, P., Visani, G. & Tura, S. (2002) Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica, 87, 12861306.
  • Allampallam, K., Shetty, V., Mundle, S., Dutt, D., Kravitz, H., Reddy, P.L., Alvi, S., Galili, N., Saberwal, G.S., Anthwal, S., Shaikh, M.W., York, A. & Raza, A. (2002) Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. International Journal of Hematology, 75, 289297.
  • Balducci, L. (2006) Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer, 106, 20872094.
  • Balleari, E., Rossi, E., Clavio, M., Congiu, A., Gobbi, M., Grosso, M., Secondo, V., Spriano, M., Timitilli, S. & Ghio, R. (2006) Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Annals of Hematology, 85, 174180.
  • Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189199.
  • Bokemeyer, C., Aapro, M.S., Courdi, A., Foubert, J., Link, H., Osterborg, A., Repetto, L. & Soubeyran, P. (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. European Journal of Cancer, 40, 22012216.
  • Bowen, D.T. & Hellstrom-Lindberg, E. (2001) Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy? Leukemia Research, 25, 1921.
  • Brooks, R., Rabin, R. & De Charro, F. (eds.) (2003) The Measurement and Validation of Health Status Using EQ-5D: A European Perspective. Evidence from the EuroQol BIOMED Research Programme. Kluwer Academic Publishers, Rotterdam.
  • Canon, J.L., Vansteenkiste, J., Bodoky, G., Mateos, M.V., Bastit, L., Ferreira, I., Rossi, G. & Amado, R.G. (2006) Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. Journal of the National Cancer Institute, 98, 273284.
  • Casadevall, N., Durieux, P., Dubois, S., Hemery, F., Lepage, E., Quarre, M.C., Damaj, G., Giraudier, S., Guerci, A., Laurent, G., Dombret, H., Chomienne, C., Ribrag, V., Stamatoullas, A., Marie, J.P., Vekhoff, A., Maloisel, F., Navarro, R., Dreyfus, F. & Fenaux, P. (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood, 104, 321327.
  • Catenacci, D.V. & Schiller, G.J. (2005) Myelodysplasic syndromes: a comprehensive review. Blood Reviews, 19, 301319.
  • Cella, D., Eton, D.T., Lai, J.S., Peterman, A.H. & Merkel, D.E. (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management, 24, 547561.
  • Cheson, B.D., Bennett, J.M., Kantarjian, H., Pinto, A., Schiffer, C.A., Nimer, S.D., Lowenberg, B., Beran, M., De Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Wijermans, P.W., Gore, S. & Greenberg, P.L. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 96, 36713674.
  • Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., De Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A., Kantarjian, H., Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., De Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. & Kantarjian, H. (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419425.
  • Faderl, S. & Kantarjian, H.M. (2004) Novel therapies for myelodysplastic syndromes. Cancer, 101, 226241.
  • Gardin, C. & Fenaux, P. (2004) Supportive care including growth factors in myelodysplastic syndromes. Reviews in Clinical and Experimental Hematology, 8, E3.
  • Glaspy, J., Vadhan-Raj, S., Patel, R., Bosserman, L., Hu, E., Lloyd, R.E., Boccia, R.V., Tomita, D. & Rossi, G. (2006) Randomized comparison of every 2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. Journal of Clinical Oncology, 24, 22902297.
  • Golshayan, A.R., Jin, T., Maciejewski, J., Fu, A.Z., Bershadsky, B., Kattan, M.W., Kalaycio, M.E., Sekeres, M.A., Golshayan, A.-R., Jin, T., Maciejewski, J., Fu, A.Z., Bershadsky, B., Kattan, M.W., Kalaycio, M.E. & Sekeres, M.A. (2007) Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. British Journal of Haematology, 137, 125132.
  • Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes.(see comment) (erratum appears in Blood 1998 Feb 1;91(3):1100). Blood, 89, 20792088.
  • Greenberg, P.L., Baer, M.R., Bennett, J.M., Bloomfield, C.D., DeCastro, C.M., Deeg, H.J., Devetten, M., Emanuel, P.D., Erba, H.P., Estey, E., Foran, J., Gore, S.D., Millenson, M., Navarro, W., Nimer, S.D., O’Donnell, M.R., Saba, H.I., Spiers, K., Stone, R.M. & Tallman, M.S. (2006) Clinical practice guidelines in oncology: myelodysplastic syndromes. v.4.2006 ed: National Comprehensive Cancer Network. http://www.nccn.org. Accessed August 23, 2006.
  • Gupta, P., LeRoy, S.C., Luikart, S.D., Bateman, A. & Morrison, V.A. (1999) Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leukemia Research, 23, 953959.
  • Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M.H., Schipperus, M.R., Juvonen, E., Taylor, K., Belch, A., Altes, A., Martinelli, G., Watson, D., Matcham, J., Rossi, G. & Littlewood, T.J. (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. British Journal of Haematology, 122, 394403.
  • Hellstrom-Lindberg, E. (2005) Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. Hematology (Am Soc Hematol Educ Program), 161166.
  • Hellstrom-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I.M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Nilsson-Ehle, H., Samuelsson, J., Tangen, J.M., Winqvist, I., Oberg, G., Osterborg, A. & Ost, A. (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood, 92, 6875.
  • Hellstrom-Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I.M., Dybedal, I., Grimfors, G., Hesse-Sundin, E., Hjorth, M., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Oberg, G., Porwit-MacDonald, A., Radlund, A., Samuelsson, J., Tangen, J.M., Winquist, I. & Wisloff, F. (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology, 120, 10371046.
  • Herrington, J.D., Davidson, S.L., Tomita, D.K., Green, L., Smith, R.E. & Boccia, R.V. (2005) Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. American Journal of Health-System Pharmacy, 62, 5462.
  • Hofmann, W.K. & Koeffler, H.P. (2005) Myelodysplastic syndrome. Annual Review of Medicine, 56, 116.
  • Jadersten, M., Montgomery, S.M., Dybedal, I., Porwit-MacDonald, A., Hellstrom-Lindberg, E., Jadersten, M., Montgomery, S.M., Dybedal, I., Porwit-MacDonald, A. & Hellstrom-Lindberg, E. (2005) Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood, 106, 803811.
  • Jadersten, M., Malcovati, L., Dybedal, I., Della Porta, M., Invernizzi, R., Montgomery, S.M., Pascutto, C., Portwit-MacDonald, A., Cazzola, M. & Hellstrom-Lindberg, E. (2006) Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need. Blood, 108, 521 (Abstract).
  • Jelkmann, W.E., Fandrey, J., Frede, S. & Pagel, H. (1994) Inhibition of erythropoietin production by cytokines. Implications for the anemia involved in inflammatory states. Annals of the New York Academy of Sciences, 718, 300309.
  • Kotasek, D., Steger, G., Faught, W., Underhill, C., Poulsen, E., Colowick, A.B., Rossi, G. & Mackey, J. (2003) Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. European Journal of Cancer, 39, 20262034.
  • Kurtin, S.E. (2006) Advances in the management of low- to intermediate-risk myelodysplastic syndrome: integrating the National Comprehensive Cancer Network guidelines. Clinical Journal of Oncology Nursing, 10, 197208.
  • Mannone, L., Gardin, C., Quarre, M.C., Bernard, J.F., Vassilieff, D., Ades, L., Park, S., Vaultier, S., Hamza, F., Beyne-rauzy, M.O., Cheze, S., Giraudier, S., Agape, P., Legros, L., Voillat, L., Dreyfus, F. & Fenaux, P. (2006) High-dose darbepoetin alfa in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. British Journal of Haematology, 133, 513519.
  • Musto, P., Lanza, F., Balleari, E., Grossi, A., Falcone, A., Sanpaolo, G., Bodenizza, C., Scalzulli, P.R., La Sala, A., Campioni, D., Ghio, R., Cascavilla, N. & Carella, A.M. (2005) Darbepoetin alfa for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. British Journal of Haematology, 128, 204209.
  • Patton, J.F., Sullivan, T., Mun, Y., Reeves, T., Rossi, G. & Wallace, J.F. (2005) A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome. The Journal of Supportive Oncology, 3, 419426.
  • Raza, A., Mundle, S., Shetty, V., Alvi, S., Chopra, H., Span, L., Parcharidou, A., Dar, S., Venugopal, P., Borok, R., Gezer, S., Showel, J., Loew, J., Robin, E., Rifkin, S., Alston, D., Hernandez, B., Shah, R., Kaizer, H. & Gregory, S. (1996) Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. International Journal of Hematology, 63, 265278.
  • Rizzo, J.D., Lichtin, A.E., Woolf, S.H., Seidenfeld, J., Bennett, C.L., Cella, D., Djulbegovic, B., Goode, M.J., Jakubowski, A.A., Lee, S.J., Miller, C.B., Rarick, M.U., Regan, D.H., Browman, G.P. & Gordon, M.S. (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood, 100, 23032320.
  • Robinson, D.M. & Easthope, S.E. (2005) Darbepoetin alfa: its use in anemia associated with chronic kidney disease. BioDrugs, 19, 327343.
  • Rodgers, G.M., Cella, D., Chanan-Khan, A., Chesney, C., Cleeland, C., Coccia, P.F., Demetri, G.D., Djulbegovic, B., Garst, J.L., Gore, M., Kraut, E.H., Lin, W.-C., Millenson, M., Mock, V., Reinke, D., Rosenthal, J. & Sabbatini, P. (2005) Cancer- and treatment-related anemia: clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 3, 772789.
  • Rose, E.H., Abels, R.I., Nelson, R.A., McCullough, D.M. & Lessin, L. (1995) The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). British Journal of Haematology, 89, 831837.
  • Schwartzberg, L.S., Yee, L.K., Senecal, F.M., Charu, V., Tomita, D., Wallace, J. & Rossi, G. (2004) A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist, 9, 696707.
  • Sekeres, M.A. & List, A. (2006) Immunomodulation in myelodysplastic syndromes. Best Practice & Research. Clinical Haematology, 19, 757767.
  • Sekeres, M.A., Fu, A.Z., Maciejewski, J.P., Golshayan, A.R., Kalaycio, M.E. & Kattan, M.W. (2007) A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Cancer, 109, 11251132.
  • Spiriti, M.A., Latagliata, R., Niscola, P., Cortelezzi, A., Francesconi, M., Ferrari, D., Volpe, E., Clavio, M., Grossi, A., Reyes, M.T., Musto, P., Mitra, M.E., Azzara, A., Pagnini, D., D’Arena, G., Spadano, A., Balleari, E., Pecorari, P., Capochiani, E., De Biasi, E., Perego, D., Monarca, B., Pisani, F., Scaramella, G. & Petti, M.C. (2005) Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Annals of Hematology, 84, 167176.
  • Stasi, R., Abruzzese, E., Lanzetta, G., Terzoli, E. & Amadori, S. (2005) Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Annals of Oncology, 16, 19211927.
  • Stifter, G., Heiss, S., Gastl, G., Tzankov, A. & Stauder, R. (2005) Over-expression of tumor necrosis factor-alfa in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. European Journal of Haematology, 75, 485491.
  • Tehranchi, R. (2006) Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes. Medical Oncology, 23, 3749.
  • Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., Siena, S., Gateley, J., Tomita, D., Colowick, A.B. & Musil, J. (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute, 94, 12111220.
  • Vardiman, J.W., Harris, N.L. & Brunning, R.D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 22922302.
  • Verma, A. & List, A.F. (2005) Cytokine targets in the treatment of myelodysplastic syndromes. Current Hematology Reports, 4, 429435.